Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2018. Natl Vital Stat Rep. 2019;68:1–47.
Centers for Disease Control and Prevention. Preterm birth [Internet]. Available from: http://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm. Accessed 7/11/20.
• Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-term cardiovascular risks associated with adverse pregnancy outcomes. J Am Coll Cardiol. 2019;73:2106–16. This review highlights the epidemiology and possible mechanisms of adverse pregnancy outcomes and future CVD, incorporating recent data.
Kuklina E, Callaghan W. Chronic heart disease and severe obstetric morbidity among hospitalisations for pregnancy in the USA: 1995-2006: heart disease and severe morbidity in USA. BJOG Int J Obstet Gynaecol. 2011;118:345–52.
Correa A, Bardenheier B, Elixhauser A, Geiss LS, Gregg E. Trends in prevalence of diabetes among delivery hospitalizations, United States, 1993-2009. Matern Child Health J. 2015;19:635–42.
Sharma G, Lindley K, Grodzinsky A. Cardio-obstetrics. J Am Coll Cardiol. 2020;75:1355–9.
Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S, et al. Potential markers of preeclampsia – a review. Reprod Biol Endocrinol. 2009;7:70.
Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, et al. Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet. 2010;375:1609–23.
Wanderer JP, Leffert LR, Mhyre JM, Kuklina EV, Callaghan WM, Bateman BT. Epidemiology of obstetric-related ICU admissions in Maryland: 1999–2008*. Crit Care Med. 2013;41:1844–52.
Hypertension in Pregnancy: Executive Summary. Obstetrics & Gynecology. 2013;122(5):1122–31.
Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
Silverberg O, Park AL, Cohen E, Fell DB, Ray JG. Premature cardiac disease and death in women whose infant was preterm and small for gestational age: a retrospective cohort study. JAMA Cardiol. 2018;3:247–51.
Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326:845.
Ray JG, Schull MJ, Kingdom JC, Vermeulen MJ. Heart failure and dysrhythmias after maternal placental syndromes: HAD MPS study. Heart. 2012;98:1136–41.
Thilaganathan B, Kalafat E. Cardiovascular system in preeclampsia and beyond. Hypertension. 2019;73:522–31.
Kalafat E, Sukur YE, Abdi A, Thilaganathan B, Khalil A. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. Ultrasound Obstet Gynecol. 2018;52:706–14.
Giannakou K, Evangelou E, Papatheodorou SI. Genetic and non-genetic risk factors for pre-eclampsia: umbrella review of systematic reviews and meta-analyses of observational studies: genetic and non-genetic risk factors for PE. Ultrasound Obstet Gynecol. 2018;51:720–30.
Egeland GM, Klungsøyr K, Øyen N, Tell GS, Næss Ø, Skjærven R. Preconception cardiovascular risk factor differences between gestational hypertension and preeclampsia: cohort Norway study. Hypertension. 2016;67:1173–80.
Perry H, Khalil A, Thilaganathan B. Preeclampsia and the cardiovascular system: an update. Trends Cardiovasc Med. 2018;28:505–13.
Serrano NC, Guio-Mahecha E, Quintero-Lesmes DC, Becerra-Bayona S, Paez MC, Beltran M, et al. Lipid profile, plasma apolipoproteins, and pre-eclampsia risk in the GenPE case-control study. Atherosclerosis. 2018;276:189–94.
Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078.
Heida KY, Franx A, van Rijn BB, Eijkemans MJC, Boer JMA, Verschuren MWM, et al. Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension. 2015;66:1116–22.
• Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, et al. Long-term cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol. 2019;74:2743–54. This study showed that hypertensive disorders of pregnancy are associated with accelerated cardiovascular aging and may be useful to refine CVD risk assessments.
Leslie MS, Briggs LA. Preeclampsia and the risk of future vascular disease and mortality: a review. J Midwif Women’s Health. 2016;61:315–24.
White WM, Mielke MM, Araoz PA, Lahr BD, Bailey KR, Jayachandran M, et al. A history of preeclampsia is associated with a risk for coronary artery calcification 3 decades later. Am J Obstet Gynecol. 2016;214:519.e1–8.
Zoet GA, Benschop L, Boersma E, Budde RPJ, Fauser BCJM, van der Graaf Y, et al. Prevalence of subclinical coronary artery disease assessed by coronary computed tomography angiography in 45- to 55-year-old women with a history of preeclampsia. Circulation. 2018;137:877–9.
Beckman JP, Camp JJ, Lahr BD, Bailey KR, Kearns AE, Garovic VD, et al. Pregnancy history, coronary artery calcification and bone mineral density in menopausal women. Climacteric. 2018;21:53–9.
Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944–51.
Feig DS, Shah BR, Lipscombe LL, Wu CF, Ray JG, Lowe J, et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. Middleton P, editor. PLoS Med. 2013;10:e1001425.
Veerbeek JHW, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, et al. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension. 2015;65:600–6.
Al-Nasiry S, Ghossein-Doha C, Polman S, Lemmens S, Scholten R, Heidema W, et al. Metabolic syndrome after pregnancies complicated by pre-eclampsia or small-for-gestational-age: a retrospective cohort. BJOG: Int J Obstet Gy. 2015;122:1818–23.
Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy. J Am Coll Cardiol. 2013;62:1715–23.
Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–8.
Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular disease. Cardiovasc Res. 2014;101:579–86.
Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011;58:709–15.
Scantlebury DC, Kane GC, Wiste HJ, Bailey KR, Turner ST, Arnett DK, et al. Left ventricular hypertrophy after hypertensive pregnancy disorders. Heart. 2015;101:1584–90.
Tangren JS, Powe CE, Ankers E, Ecker J, Bramham K, Hladunewich MA, et al. Pregnancy outcomes after clinical recovery from AKI. JASN. 2017;28:1566–74.
Stergiotou I, Bijnens B, Cruz-Lemini M, Figueras F, Gratacos E, Crispi F. Maternal subclinical vascular changes in fetal growth restriction with and without pre-eclampsia: maternal vascular remodeling in FGR and PE. Ultrasound Obstet Gynecol. 2015;46:706–12.
Sep S, Schreurs M, Bekkers S, Kruse A, Smits L, Peeters L. Early-pregnancy changes in cardiac diastolic function in women with recurrent pre-eclampsia and in previously pre-eclamptic women without recurrent disease: diastolic function early in recurrent pre-eclampsia. BJOG Int J Obstet Gynaecol. 2011;118:1112–9.
Ghossein-Doha C, Spaanderman MEA, Al Doulah R, Van Kuijk SM, Peeters LLH. Maternal cardiac adaptation to subsequent pregnancy in formerly pre-eclamptic women according to recurrence of pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47:96–103.
Milic NM, Milin-Lazovic J, Weissgerber TL, Trajkovic G, White WM, Garovic VD. Preclinical atherosclerosis at the time of pre-eclamptic pregnancy and up to 10 years postpartum: systematic review and meta-analysis: pre-eclampsia and preclinical atherosclerosis. Ultrasound Obstet Gynecol. 2017;49:110–5.
Brouwers L, van der Meiden-van Roest A, Savelkoul C, Vogelvang T, Lely A, Franx A, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. BJOG: Int J Obstet Gy. 2018;125:1642–54.
Theilen LH, Meeks H, Fraser A, Esplin MS, Smith KR, Varner MW. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol. 2018;219:107.e1–6.
American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S13–28.
• Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131:e49–64. ACOG's practice bulletin on gestational diabetes mellitus provides updated guidance on management of GDM.
Garrison A. Screening, diagnosis, and management of gestational diabetes mellitus. Am Fam Physician. 2015;91:460–7.
Diabetes During Pregnancy | Maternal Infant Health | Reproductive Health | CDC [Internet]. [cited 2020 Apr 4]. Available from: https://www.cdc.gov/reproductivehealth/maternalinfanthealth/diabetes-during-pregnancy.htm.
Bellamy L, Casas J-P, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.
Kaul P, Savu A, Nerenberg KA, Donovan LE, Chik CL, Ryan EA, et al. Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a population-level analysis. Diabet Med. 2015;32:164–73.
Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. 2006
Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. J Clin Endocrinol Metab. 2010;95:4345–53.
Pirkola J, Pouta A, Bloigu A, Miettola S, Hartikainen AL, Järvelin MR, et al. Prepregnancy overweight and gestational diabetes as determinants of subsequent diabetes and hypertension after 20-year follow-up. J Clin Endocrinol Metab. 2010;95:772–8.
• Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62:905–14. This meta-analysis evaluated the impact of gestational diabetes on future CVD risk and demonstrated that the increased risk was independent of the subsequent development of type 2 diabetes.
Harreiter J, Dovjak G, Kautzky-Willer A. Gestational diabetes mellitus and cardiovascular risk after pregnancy. Women Health. 2014;10:91–108.
Vrachnis N, Augoulea A, Iliodromiti Z, Lambrinoudaki I, Sifakis S, Creatsas G. Previous gestational diabetes mellitus and markers of cardiovascular risk. Int J Endocrinol. 2012;2012:1–6.
Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 2005;90:3983–8.
Bo S, Valpreda S, Menato G, Bardelli C, Botto C, Gambino R, et al. Should we consider gestational diabetes a vascular risk factor? Atherosclerosis. 2007;194:72–9.
Practice Bulletin No. 171: Management of Preterm Labor. Obstetrics & Gynecology. 2016;128:e155–64.
• Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O’Brien S, et al. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. JAHA [Internet]. 2018 [cited 2020 Jul 9];7. Available from: https://doi.org/10.1161/JAHA.117.007809. This study adds to prior literature on preterm delivery and maternal CVD by conducting a meta-analysis that incorporated more recent studies with larger sample sizes, showing that preterm delivery is associated wtih maternal CVD and mortality.
Rich-Edwards JW, Klungsoyr K, Wilcox AJ, Skjaerven R. Duration of pregnancy, even at term, predicts long-term risk of coronary heart disease and stroke mortality in women: a population-based study. Am J Obstet Gynecol. 2015;213:518.e1–8.
Hastie CE, Smith GC, MacKay DF, Pell JP. Maternal risk of ischaemic heart disease following elective and spontaneous pre-term delivery: retrospective cohort study of 750 350 singleton pregnancies. Int J Epidemiol. 2011;40:914–9.
Bryant AS, Worjoloh A, Caughey AB, Washington AE. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. Am J Obstet Gynecol. 2010;202:335–43.
Bentley-Lewis R, Powe C, Ankers E, Wenger J, Ecker J, Thadhani R. Effect of race/ethnicity on hypertension risk subsequent to gestational diabetes mellitus. Am J Cardiol. 2014;113:1364–70.
Silva LM, Coolman M, Steegers EA, Jaddoe VW, Moll HA, Hofman A, et al. Low socioeconomic status is a risk factor for preeclampsia: the Generation R Study. J Hypertens. 2008;26:1200–8.
Caughey AB, Cheng YW, Stotland NE, Washington AE, Escobar GJ. Maternal and paternal race/ethnicity are both associated with gestational diabetes. YMOB. 2010;202:616.e1–5.
Manuck TA. Racial and ethnic differences in preterm birth: a complex, multifactorial problem. Semin Perinatol. 2017;41:511–8.
Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in neonatal mortality--United States, 1989–2001. MMWR Morb Mortal Wkly Rep. 2004;53:655–8.
Tucker MJ, Berg CJ, Callaghan WM, Hsia J. The black-white disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. American Journal of Public Health. Am Publ Health Assoc. 2007;97:247–51.
Shahul S, Tung A, Minhaj M, Nizamuddin J, Wenger J, Mahmood E, et al. Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia/eclampsia. Hypertens Pregnancy. 2015;34:506–15.
Bo S, Menato G, Bardelli C, Lezo A, Signorile A, Repetti E, et al. Low socioeconomic status as a risk factor for gestational diabetes. Diabetes Metab. 2002;28:139–40.
Messer LC, Vinikoor LC, Laraia BA, Kaufman JS, Eyster J, Holzman C, et al. Socioeconomic domains and associations with preterm birth. Soc Sci Med. 2008;67:1247–57.
• Ross KM, Guardino C, Dunkel Schetter C, Hobel CJ. Interactions between race/ethnicity, poverty status, and pregnancy cardio-metabolic diseases in prediction of postpartum cardio-metabolic health. Ethn Health. 2018:1–16. This study assessed various socioeconomic and racial/ethnic factors in their association with pregnancy complications and cardiometabolic risk.
Nakimuli A, Chazara O, Byamugisha J, Elliott AM, Kaleebu P, Mirembe F, et al. Pregnancy, parturition and preeclampsia in women of African ancestry. Am J Obstet Gynecol. 2014;210:510–520.e1.
ACOG Committee Opinion No. 743: low-dose Aspirin use during pregnancy. Obstet Gynecol 2018;132:e44–52.
Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261.
Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, et al. The use of Aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A 2 to prostacyclin in relatively high risk pregnancies. N Engl J Med. 1989;321:351–6.
Naseem H, Dreixler J, Mueller A, Tung A, Dhir R, Chibber R, et al. Antepartum aspirin administration reduces activin A and cardiac global longitudinal strain in preeclamptic women. JAHA. 2020;9:e015997. https://doi.org/10.1161/JAHA.119.015997
LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:819.
Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:285–93.
van Vliet EOG, Askie LA, Mol BWJ, Oudijk MA. Antiplatelet agents and the prevention of spontaneous preterm birth: a systematic review and meta-analysis. Obstet Gynecol. 2017;129:327–36.
Tan MY, Poon LC, Rolnik DL, Syngelaki A, de Paco Matallana C, Akolekar R, et al. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol. 2018;52:52–9.
Zhang J, Han L, Li W, Chen Q, Lei J, Long M, et al. Early prediction of preeclampsia and small-for-gestational-age via multi-marker model in Chinese pregnancies: a prospective screening study. BMC Preg Childbirth. 2019;19:304.
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994;343:619–29.
Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.
Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338:701–5.
Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Lancet. 1993;341:396–400.
• Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695. In this USPSTF statement, the authors conduct a systematic review of low dose aspirin for the prevention of preeclampsia and analyze data that led to the current recommendations on the use of low dose aspirin in women at elevated risk for preeclampsia.
Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol. 2018;219:399.e1–6.
McCowan LM, Harding J, Roberts A, Barker S, Ford C, Stewart A. Administration of low-dose aspirin to mothers with small for gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a randomised double-blind controlled trial. Br J Obstet Gynaecol. 1999;106:647–51.
Trudinger BJ, Cook CM, Thompson RS, Giles WB, Connelly A. Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. Am J Obstet Gynecol. 1988;159:681–5.
Roberge S, Sibai B, McCaw-Binns A, Bujold E. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Amer J Perinatol. 2016;33:781–5.
Rich-Edwards JW, Stuart JJ, Skurnik G, Roche AT, Tsigas E, Fitzmaurice GM, et al. Randomized trial to reduce cardiovascular risk in women with recent preeclampsia. J Women's Health. 2019;28:1493–504.
Mann S, Hollier LM, McKay K, Brown H. What we can do about maternal mortality — and how to do it quickly. N Engl J Med. 2018;379:1689–91.
• Brown HL, Warner JJ, Gianos E, Gulati M, Hill AJ, Hollier LM, et al. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American college of obstetricians and gynecology. Circulation. 2018;137:e843–52. This statement from the AHA and ACOG highlights the importance of coordinated healthcare delivery among OB/GYNs and cardiologists in multiple areas of preventive care.
ACOG Practice Bulletin No. 212: pregnancy and heart disease. Obstet Gynecol. 2019;133(5):e320–56.
ACOG Committee on Obstetric Practice. Presidential Task Force on Redefining the Postpartum Visit Committee on Obstetric Practice. Obstet Gynecol. 2018;131(5):e140–50.
• Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications: systematic review and meta-analysis. Circulation. 2019;139:1069–79. This systematic review incorporates a broader range of pregnancy complications outside of the commonly studied preeclampsia, gestational diabetes, or preterm delivery and demonstrates their increased association with future CVD.
Markovitz AR, Stuart JJ, Horn J, Williams PL, Rimm EB, Missmer SA, et al. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. Eur Heart J. 2019;40:1113–20.
Stuart JJ, Tanz LJ, Cook NR, Spiegelman D, Missmer SA, Rimm EB, et al. Hypertensive disorders of pregnancy and 10-year cardiovascular risk prediction. J Am Coll Cardiol. 2018;72:1252–63.
Timpka S, Fraser A, Schyman T, Stuart JJ, Åsvold BO, Mogren I, et al. The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women. Eur J Epidemiol. 2018;33:1003–10.
Grand’Maison S, Pilote L, Okano M, Landry T, Dayan N. Markers of vascular dysfunction after hypertensive disorders of pregnancy: a systematic review and meta-analysis. Hypertension. 2016;68:1447–58.
Ciftci FC, Caliskan M, Ciftci O, Gullu H, Uckuyu A, Toprak E, et al. Impaired coronary microvascular function and increased intima–media thickness in preeclampsia. J Am Soc Hyperten. 2014;8:820–6.
Timpka S, Stuart JJ, Tanz LJ, Rimm EB, Franks PW, Rich-Edwards JW. Lifestyle in progression from hypertensive disorders of pregnancy to chronic hypertension in Nurses’ Health Study II: observational cohort study. BMJ. 2017:j3024.